SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
OncoCyte Corporation (OCX) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+150%).
- Analyst consensus target $8.00 (+150% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 45/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
25/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — OCX
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio24.05
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.65
Book Value / Share$0.00
Revenue / Share$0.13
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$8.00 (+150%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-8.42 |
$0.00 |
$-11.17M |
- |
| 2017 |
$-12.83 |
$0.00 |
$-19.38M |
- |
| 2018 |
$-8.32 |
$0.00 |
$-15.75M |
- |
| 2019 |
$-8.71 |
$0.00 |
$-22.33M |
- |
| 2020 |
$-9.14 |
$1.22M |
$-29.93M |
-2461.5% |
| 2021 |
$-14.42 |
$7.73M |
$-64.1M |
-829.5% |
| 2022 |
$-13.26 |
$958K |
$-73.44M |
-7666% |
| 2023 |
$-3.75 |
$1.5M |
$-27.78M |
-1848.4% |
| 2024 |
$-4.66 |
$1.88M |
$-60.66M |
-3225% |
| 2025 |
$-1.65 |
$4.06M |
$-50.22M |
-1238.5% |
